International Orthopaedics

, Volume 30, Issue 3, pp 143–146

Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population

  • Wei Sun
  • Zi–rong Li
  • Zhen–cai Shi
  • Nian–fei Zhang
  • Yuan–chun Zhang
Original Paper


The purpose of this study was to detect changes in coagulation and fibrinolysis of post-severe acute respiratory syndrome (SARS) Chinese patients with osteonecrosis, investigate the aetiology of post-SARS osteonecrosis (ON), and select the sensitive molecular markers for identifying the susceptible population. For this study, blood samples were collected from 88 patients with post-SARS ON and 52 healthy people. Activated partial thromboplastin time (APTT), protein C (PC), antithrombin III (AT–III), plasminogen activator inhibitor (PAI), activated protein C resistance (APC–R), plasminogen (PLG), von Willebrand’s factor(vWF), D–dimer (D–D), fibrinogen (Fib), and homocysteine (HCY) were examined by enzyme-linked immunosorbent assay (ELISA). We noted that blood agents of patients with ON changed obviously. APTT, PC, AT–III, PAI, APC–R, and PLG were significantly different between the two groups. Hypercoagulation and hypofibrinolysis were found in patients with post-SARS ON. Therefore, these examinations can be used to screen a population susceptible to ON. Measurements of APTT, PC, AT–III, PAI, APC–R, and PLG are sensitive blood tests for screening purposes.


Le but de cette étude est de détecter les troubles de la coagulation et de la fibrinolyse chez les patients ayant présenté, en Chine, un SRAS, avec ostéonécrose, d’étudier l’étiologie des ostéonécroses post-SRAS et de sérier la population susceptible de présenter de telles pathologies. Pour cette étude, des échantillons de sang ont été collectés chez 88 patients ayant présenté un SRAS avec ostéonéchrose et, sur une population témoin de 52 autres patients. Le temps d’activation partielle de la thromboplastie (APT), la protéine C (PC), l’antithrombine III (AT III), l’activateur d’inhibition du plasminogène (PLG), l’activateur de la résistance de la protéine C (PAC R), le plasminogène (PLG), le facteur de Willebrand (vWF), les D–Dimmer (D–D), le fibrinogène (Fib) et l’homocystéine (HCY) ont été analysés par la technique d’Elisa. Nous avons noté que les facteurs sanguins de ces patients, présentant une ostéonéchrose présentaient un changement significatif (APTT, PC, AT–III, PAI, APC–R, PLG). Cette différence étant significative également entre les deux groupes. Nous avons trouvé chez ces patients une hypercoagulation avec une hypofibrinolyse après post-SRAS. Ces examens, peuvent être utilisés en routine pour dépister les populations susceptibles de présenter une ostéonécrose après SRAS, les facteurs sensitifs du dépistage étant l’APTT, PC, A T–III, PAI, APC–R et le PLG.


  1. 1.
    Jones JP Jr (1992) Intravascular coagulation and osteonecrosis. Clin Orthop 277:41–53PubMedGoogle Scholar
  2. 2.
    Miller KD, Masur H, Jones EC et al (2002) High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 137:17–25PubMedGoogle Scholar
  3. 3.
    Bottaro EG, Figueroa RH, Scapellato PG et al (2004) Osteonecrosis in HIV-infected patients. Medicina (B Aires) 64(4):325–331Google Scholar
  4. 4.
    Jones JP Jr, Sakovich L, Anderson CE (1974) Experimentally produced osteonecrosis as a result of fat embolism. In: Beckman EL, Elliott DH, Smith EM (eds) Dysbarism-Related Osteonecrosis. HEW Publ (NIOSH) 75–153, Washington, DC, U.S. Government Printing Office, p 117Google Scholar
  5. 5.
    Jones JP Jr (1994) Concepts of etiology and early pathogenesis of osteonecrosis. In: Schafer M (ed) Instructional course lectures 43. American Academy of Orthopaedic Surgeons, Rosemont, IL, p 499Google Scholar
  6. 6.
    Starklint H, Lausten CS, Arnoldi CC (1995) Microvascular obstruction in avascular necrosis: immunohistochemistry of 14 femoral heads. Acta Orthop Scand 66:9–12PubMedGoogle Scholar
  7. 7.
    Jones JP (1997) Risk factors potentially activating intravascular coagulation and causing nontraumatic osteonecrosis. In: Urbaniak JR, Jones JP Jr (eds) Osteonecrosis: etiology, diagnosis, and treatment. American Academy of Orthopaedic Surgeons, Rosemont, IL, p 89Google Scholar
  8. 8.
    Jones LC, Mont MA, Le TB et al (2003) Procoagulants and Osteonecrosis. J Rheumatol 30:783–791PubMedGoogle Scholar
  9. 9.
    Glueck CJ, Freiberg RA, Wang P (2003) Role of thrombosis in osteonecrosis. Curr Hematol Rep 2:417–422PubMedGoogle Scholar
  10. 10.
    Nilsson IM, Krook H, Sternby HH et al (1961) Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Med Scand 169:323–337PubMedCrossRefGoogle Scholar
  11. 11.
    Glueck CJ, Glueck HI, Mieczkowski L et al (1993) Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost 69:460–465PubMedGoogle Scholar
  12. 12.
    Glueck CJ, Freiberg R, Glueck HI et al (1994) Hypofibrinolysis: a common, major cause of osteonecrosis. Am J Hematol 45:156–166PubMedCrossRefGoogle Scholar
  13. 13.
    Glueck CJ, Freiberg R, Glueck HI et al (1995) Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein (a), and therapy with Stanozolol. Am J Hematol 48:213–220PubMedCrossRefGoogle Scholar
  14. 14.
    Van Veldhuizen PJ, Neff J, Murphey MD et al (1993) Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol 44:243–248PubMedCrossRefGoogle Scholar
  15. 15.
    Glueck CJ, Freiberg RA, Fontaine RN et al (2001) Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop 386:19–33PubMedCrossRefGoogle Scholar
  16. 16.
    Glueck CJ, Fontaine RN, Gruppo R et al (1999) The plasminogen activator inhibitor–1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop 366:133–146PubMedCrossRefGoogle Scholar
  17. 17.
    Glueck CJ, Freiberg R, Tracy T et al (1997) Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis. Clin Orthop 334:43–56PubMedGoogle Scholar
  18. 18.
    Jones JP (2000) Epidemiological risk factors for non-traumatic osteonecrosis. Orthopede 29:370–379Google Scholar
  19. 19.
    Korompilias AV, Gilkeson GS, Ortel TL et al (1997) Anticardiolipin antibodies and osteonecrosis of the femoral head. Clin Orthop 345:174–180PubMedGoogle Scholar
  20. 20.
    Kubo T, Tsuhi H, Yamamoto T et al (2000) Antithrombin III deficiency in a patient with multifocal osteonecrosis. Clin Orthop 378:306–311PubMedCrossRefGoogle Scholar
  21. 21.
    Berger CE, Kroner A, Stiegler H et al (2002) Hypofibrinolysis, lipoprotein (a) and plasminogen activator inhibitor. Clin Orthop 397:342–349PubMedCrossRefGoogle Scholar
  22. 22.
    Cosgriff SW (1951) Thromboembolic complications associated with ACTH and cortisone therapy. JAMA 147:924–926Google Scholar
  23. 23.
    Aaron RK, Ciombor DM (2001) Coagulopathies and osteonecrosis. Curr Opin Orthop 12:378–383CrossRefGoogle Scholar
  24. 24.
    Bjorkman A, Svensson PJ, Hillarp A et al (2004) Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop 425:168–172PubMedCrossRefGoogle Scholar
  25. 25.
    Charalampos GZ, Geotge V, Eleni D et al (2004) Genetic background of osteonecrosis: associated with thrombophilic mutations? Clin Orthop 422:251–255CrossRefGoogle Scholar
  26. 26.
    Lee JS, Koo KH, Ha YC et al (2003) Role of thrombotic and fibrinolytic disorders in osteonecrosis of the femoral head. Clin Orthop 417:270–276PubMedGoogle Scholar
  27. 27.
    Zheng JM, Lu XH, Dong TH et al (2002) The study of hematological change of nontraumatic osteonecrosis of femoral head. Chin J Orthop 22:423–426Google Scholar
  28. 28.
    Mont MA, Jones LC, Rajadhyaksha AD et al (2004) Risk factors for pulmonary emboli after total hip or knee arthroplasty. Clin Orthop 422:154–163PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Wei Sun
    • 1
  • Zi–rong Li
    • 1
  • Zhen–cai Shi
    • 1
  • Nian–fei Zhang
    • 1
  • Yuan–chun Zhang
    • 1
  1. 1.Center for Osteonecrosis and Joint Preserving and Reconstruction, Department of Orthopaedic SurgeryChina–Japan Friendship HospitalBeijingPeople’s Republic of China

Personalised recommendations